Congress funds research on cosmetics chemicals linked to reproductive harm
H.R. 3749 — HER Act · Filed by Shontel Brown (D-OH) · 3 cosponsors · Introduced Jun 5, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Health and Human Services to award federal research grants studying how endocrine-disrupting chemicals in personal care products (cosmetics, shampoos, soaps, etc.) affect women's reproductive health, and to fund state-level investigation and public awareness programs on the same topic. The bill requires HHS to report findings to Congress every five years and recommend regulatory strategies to expand FDA oversight of these chemicals.
Why we flagged it
The bill's operative mechanism is straightforward: federal grant funding for research and state awareness programs on a specific reproductive health hazard. It is a research and education bill, not a regulatory change or industry carve-out.
What the text implies
- The bill's requirement that HHS recommend 'evidence-based or evidence-informed legislative or administrative strategies to increase the FDA's domain' to regulate endocrine-disrupting chemicals may eventually lead to stricter cosmetics ingredient rules, which could increase compliance costs for personal care product manufacturers and potentially reduce product availability or raise consumer prices.
- State-level investigation and awareness programs may create inconsistent regulatory expectations across states, potentially fragmenting the personal care product market if states adopt divergent standards based on grant-funded research.
The full analysis lists 3 implications of this text.
Who stands to gain
research institutions and universities (grant recipients); state health departments (grant recipients); public health advocacy organizations (potential awareness campaign contractors)